Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells by Twohig, Jason P. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/119564/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Twohig, Jason, Cardus Figueras, Ana, Andrews, Robert, Wiede, Florian, Cossins, Benjamin, Derrac
Soria, Alicia, Lewis, Myles, Townsend, Michael, Millrine, David, Hill, David, Uceda Fernandez,
Javier, Liu, Xiao, Szomolay, Barbara, Pepper, Christopher, Taylor, Philip, Pitzalis, Costantino,
Tiganis, Tony, Williams, Nigel, Jones, Gareth and Jones, Simon A. 2019. Activation of naïve CD4+
T cells re-tunes STAT1 signaling to 1 deliver unique cytokine responses in memory CD4+ T cells.
Nature Immunology 20 , pp. 458-470. 10.1038/s41590-019-0350-0 file 
Publishers page: https://doi.org/10.1038/s41590-019-0350-0 <https://doi.org/10.1038/s41590-019-
0350-0>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Activation of naïve CD4
+
 T cells re-tunes STAT1 signaling to deliver unique cytokine responses in ͳ 
memory CD4
+
 T cells ʹ 
 ͵ 
Jason P. Twohig
1,2#
, Ana Cardus Figueras
1,2#
, Robert Andrews
2
, Florian Wiede
3,4
, Benjamin C. Cossins
1,2
, Ͷ 
Alicia Derrac Soria
1,2
, Myles J. Lewis
5
, Michael J. Townsend
6
, David Millrine
1,2
, Jasmine Li
3,7
, David G. ͷ 
Hill
1,2
, Javier Uceda Fernandez
1,2,∞
, Xiao Liu
1,2
, Barbara Szomolay
1,2
, Christopher J. Pepper
8,9
, Philip R. ͸ 
Taylor
1,2
, Costantino Pitzalis
5
, Tony Tiganis
3,4
, Nigel M. Williams
10
, Gareth W. Jones
1,2,11
 & Simon A. ͹ 
Jones
1,2*
 ͺ 
 ͻ 
Affiliations: ͳͲ 
1. Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK ͳͳ 
2. Systems Immunity University Research Institute, Cardiff University, Cardiff, Wales, UK ͳʹ 
3. Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia ͳ͵ 
4. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, ͳͶ 
Australia ͳͷ 
5. Centre for Experimental Medicine & Rheumatology, William Harvey research Institute, Queen Mary’s ͳ͸ 
School of Medicine & Dentistry, London, UK ͳ͹ 
6. ITGR Diagnostics Discovery, Genentech Research & Early Development, 1 DNA Way, South San ͳͺ 
Francisco, CA94080, USA ͳͻ 
7. Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia ʹͲ 
8. Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, Wales, UK ʹͳ 
9. Brighton and Sussex Medical School, University of Sussex, Brighton, UK ʹʹ 
10. Division of Psychological Medicine & Clinical Neuroscience, School of Medicine, Cardiff University, ʹ͵ 
Cardiff, Wales, UK.  ʹͶ 
11. School of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University ʹͷ 
of Bristol, Bristol, UK ʹ͸ 
 ʹ͹ 
#
JPT and
 
ACF contributed equally to the manuscript; 
∞
JUF deceased 29th August 2018. ʹͺ 
 ʹͻ 
*
Corresponding author:
 ͵Ͳ 
Professor Simon A. Jones,  ͵ͳ 
Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, ͵ʹ 
Wales, UK.  ͵͵ 
Tel: +44 29 2068 7325; Fax: +44 29 2068 7303; E-mail: JonesSA@cf.ac.uk  ͵Ͷ 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
2 
ABSTRACT  ͵ͷ 
The cytokine IL-6 controls the survival, proliferation and effector characteristics of lymphocytes through ͵͸ 
activation of the transcription factors STAT1 and STAT3. While STAT3 activity is an ever-present feature ͵͹ 
of IL-6 signaling in CD4
+
 T cells, prior T-cell receptor activation limits the IL-6 control of STAT1 in effector ͵ͺ 
and memory populations. Here we show that STAT1 phosphorylation in response to IL-6 was regulated ͵ͻ 
by protein tyrosine phosphatases (PTPN2, PTPN22) expressed in response to the activation of naïve CD4
+
 ͶͲ 
T cells. Transcriptomic and chromatin immunoprecipitation-sequencing of IL-6 responses in naïve and Ͷͳ 
effector memory CD4
+
 T cells showed how the suppression of STAT1 activation shaped the functional Ͷʹ 
identity and effector characteristics of memory CD4
+
 T cells. Thus, protein tyrosine phosphatases induced Ͷ͵ 
by activation of naïve T cells determined the way activated or memory CD4
+
 T cells sensed and ͶͶ 
interpreted cytokine signals.  Ͷͷ 
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Naïve, activated and memory T cells display differences in their ability to respond to antigen. These Ͷ͸ 
include changes in proliferation, survival, sensitivity to antigen, dependence on co-stimulatory signals Ͷ͹ 
and alterations in T cell homing
1
. Cytokines responsible for the control of these activities often signal Ͷͺ 
through receptor-associated Janus kinases (Jak proteins) that regulate cytoplasmic transcription factors Ͷͻ 
termed signal transducers and activators of transcription (STAT)
2
. Thus, the Jak-STAT pathway senses and ͷͲ 
interprets environmental signals essential for proliferation and functional identity
2
. Here, we examined ͷͳ 
whether cytokine cues delivered by the Jak-STAT pathway can be adapted to fine-tune the effector ͷʹ 
properties of individual CD4
+
 T cell subsets.  ͷ͵ 
Studies of infection, inflammation, autoimmunity and cancer demonstrate that the cytokine IL-6 is ͷͶ 
essential for the generation of adaptive immunity
3
. Activities include the maturation and maintenance of ͷͷ 
antibody secreting B cells, and responses that shape the effector characteristics of CD4
+
 T helper (TH) ͷ͸ 
cells
3
. In this regard, mice lacking IL-6 often show deficiencies in T cell effector function and memory ͷ͹ 
recall
4, 5, 6, 7, 8, 9
. Studies also suggest that CD4
+
 T cells display differences in IL-6 responsiveness that may ͷͺ 
reflect the activation status of the T cell
7, 10, 11, 12
. How these differences arise is currently unclear.  ͷͻ 
The receptor complex responsible for IL-6 signaling consists of a type-1 cytokine receptor (IL-6R, CD126) ͸Ͳ 
and a signal-transducing β-receptor (gp130, CD130) subunit3. IL-6R is shed in response to CD4+ T cell ͸ͳ 
activation, and inflammatory T cells from sites of disease often display low IL-6R expression
7, 10, 12, 13, 14, 15, ͸ʹ 
16, 17
. IL-6 activates the latent transcription factors STAT1 and STAT3
3
. IL-6 control of STAT3 is essential for ͸͵ 
T cell recruitment and survival and the maintenance of activated T cells within inflamed tissues
11, 14, 16
. ͸Ͷ 
These STAT3-driven responses include the transactivation of anti-apoptotic regulators and genes that ͸ͷ 
determine the effector or regulatory characteristic of CD4
+
 T cells
3, 11, 18
. In contrast, IL-6 activation of ͸͸ 
STAT1 plays a more regulatory role and often determines the transcriptional output of STAT3
18, 19, 20, 21
. ͸͹ 
These studies illustrate a complex interplay between STAT1 and STAT3, and emphasize how STAT1 ͸ͺ 
signaling may shape the biological properties of IL-6
18, 20, 21, 22, 23, 24
. Significantly, CD4
+
 T cell activation has ͸ͻ 
been shown to alter IL-6 signaling through STAT1
9, 11
. Here we show that STAT1 phosphorylation in ͹Ͳ 
response to IL-6 is suppressed in activated and memory CD4
+ 
T cells and identified protein tyrosine ͹ͳ 
phosphatases as regulators of STAT1 activity. Our data further showed how this re-programming ͹ʹ 
mechanism may influence the way effector memory CD4
+
 T cells sense and interpret IL-6 signals in ͹͵ 
disease.  ͹Ͷ 
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RESULTS ͹ͷ 
Infiltrating synovial CD4
+
 T cells have altered IL-6-mediated STAT1 activation  ͹͸ 
Previous studies suggest that CD4
+
 T cell activation alters cytokine signaling through the Jak-STAT ͹͹ 
pathway
4, 9, 11
. To further these findings we established antigen-induced arthritis (AIA) in C57Bl/6 wild-͹ͺ 
type mice through immunization with methylated BSA (mBSA). Histological joint sections from day 10 of ͹ͻ 
AIA were evaluated for tyrosine phosphorylated STAT1 and STAT3 (hereafter pY-STAT1 and pY-STAT3) ͺͲ 
using immunofluorescence (Fig. 1a). While pY-STAT3 co-localized with CD3
+
 T cells, pY-STAT1 showed ͺͳ 
weak co-localization with the CD3 stain (Fig. 1a). To verify these observations, CD4
+
 T cells were isolated ͺʹ 
at day 10 of AIA from the inflamed synovium of wild-type mice and stimulated ex vivo with IL-6 ͺ͵ 
(20ng/ml). When compared to IL-6-treated CD4
+
CD25
−
CD44
lo
CD62L
hi
CD127
hi
 naïve T cells (TN cells) from ͺͶ 
the spleen of wild-type mice, intracellular flow cytometry showed that synovial CD4
+
 T cells displayed ͺͷ 
reduced pY-STAT1 staining (Fig. 1b). Both CD4
+
 T cell populations displayed comparable pY-STAT3 ͺ͸ 
responses to IL-6 (Fig. 1b). To test whether prior antigenic challenge with mBSA restricted the ability of ͺ͹ 
IL-6 to signal through STAT1, we extracted total CD4
+
 T cells from the inguinal draining lymph nodes of ͺͺ 
wild-type mice immunized with mBSA, stimulated them ex vivo for 30 min with 20ng/ml IL-6 and ͺͻ 
monitored changes in pY-STAT1 and pY-STAT3 by intracellular flow cytometry. When compared to wild-ͻͲ 
type CD4
+
 T cells from the inguinal lymph node of non-challenged mice, CD4
+
 T cells from mBSA-ͻͳ 
immunized mice showed impaired pY-STAT1 detection in response to IL-6 (Fig. 1c). This reduction in ͻʹ 
pY-STAT1 was particularly evident in activated or memory CD4
+
 T cells (Fig. 1c). ͻ͵ 
STAT1 is an important determinant of T cell effector function
20, 21, 22
. We therefore used quantitative PCR ͻͶ 
to evaluate the effector characteristics of CD4
+
 T cells from wild-type mice with AIA. Analysis was ͻͷ 
performed on CD4
+
 TN cells and CD4
+
CD25
−
CD44
hi
CD62L
lo
CD127
int-hi
 effector memory T cells (TEM cells) ͻ͸ 
from the inguinal lymph nodes of wild-type mice with AIA. Ahr, Il21, Rorgt, Il17a, Ifng and Stat3 were all ͻ͹ 
highly expressed in CD4
+
 TEM cells compared to CD4
+
 TN cells (Fig. 1d). In contrast, the expression of ͻͺ 
Socs3, a negative regulator of Jak-STAT signaling, remained comparable in both CD4
+
 T cell populations ͻͻ 
(Fig. 1d). In addition, intracellular cytokine staining of CD4
+
 TN and CD4
+ 
TEM cells showed that CD4
+ 
TEM ͳͲͲ 
cells generated increased amounts of IL-21 (Fig. 1e and Supplementary Fig. 1a). Thus, CD4
+ 
TN and CD4
+ ͳͲͳ 
TEM cells showed differences in IL-6 responsiveness. ͳͲʹ 
Control of STAT1 activity is not determined by IL-6R signaling in CD4
+
 T cells ͳͲ͵ 
To determine if T cell subsets display different IL-6 signaling properties, splenic CD4
+
 TN cells, ͳͲͶ 
CD4
+
CD25
−
CD44
hi
CD62L
hi
CD127
hi
 central memory T cells (TCM cells), CD4
+
CD25
−
CD44
lo
CD62L
lo
CD127
lo-int
 ͳͲͷ 
effector T cells (TEff cells) and CD4
+ 
TEM cells were purified from wild-type mice. These populations ͳͲ͸ 
showed differences in IL-6R and gp130 expression, but displayed a similar transient activation of ͳͲ͹ 
pY-STAT3 in response to IL-6 (Fig. 2a and Supplementary Fig. 1b). A strong induction of pY-STAT1 was ͳͲͺ 
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observed in IL-6-treated CD4
+
 TN cells, while CD4
+ 
TCM, TEff and
 
TEM cells showed impaired pY-STAT1 ͳͲͻ 
activation (Fig. 2a). A similar regulation of pY-STAT1 was also observed in human CD4
+
 T cells ͳͳͲ 
(Supplementary Fig. 1c). ͳͳͳ 
Given that activation-induced shedding of IL-6R may affect IL-6 receptor signaling, we investigated the ͳͳʹ 
IL-6 control of pY-STAT1 and pY-STAT3 in splenic CD4
+ 
TN, TCM, TEff and TEM cells from wild-type and Il6ra
-/- ͳͳ͵ 
mice. IL-6 signaling in Il6ra
-/- 
CD4
+ 
T cells was triggered by IL-6 trans-signaling using an IL-6-sIL-6R chimeric ͳͳͶ 
fusion protein (HDS)
7, 8
. Il6ra
-/- 
CD4
+
 T cells were not activated by IL-6 alone, but responded to an ͳͳͷ 
equimolar concentration of HDS, and all Il6ra
-/-
 CD4
+ 
T cells showed increased pY-STAT3 following HDS ͳͳ͸ 
stimulation (Fig. 2b). While HDS induced pY-STAT1 in Il6ra
-/-
 CD4
+
 TN cells, changes in pY-STAT1 was not ͳͳ͹ 
seen in HDS-treated CD4
+ 
TCM, TEff and TEM cells from Il6ra
-/- 
mice (Fig. 2b). Thus, the loss of STAT1 ͳͳͺ 
signaling in activated CD4
+
 T cells is independent of changes in IL-6R regulation. A similar pattern of ͳͳͻ 
pY-STAT1 regulation was noted in wild-type CD4
+
 T cells stimulated with IL-27 or IFN-γ (Fig. 2c and ͳʹͲ 
Supplementary Fig. 2d), suggesting the control of STAT1 phosphorylation was not unique to IL-6.  ͳʹͳ 
TCR activation regulates IL-6R signaling in CD4
+
 T cells  ͳʹʹ 
To investigate whether prior TCR engagement contributed to the changes in STAT1 activation in ͳʹ͵ 
activated or memory CD4
+
 T cells we compared IL-6 signaling in CD4
+
 TN cells and CD4
+
 T cells previously ͳʹͶ 
activated with antibodies against CD3 and CD28. Wild-type CD4
+
 TN cells were cultured for 72h with ͳʹͷ 
antibodies against CD3 and CD28 followed by a 48h culture in fresh media, in the absence of exogenous ͳʹ͸ 
stimulation. This rest period restored the surface expression of IL-6R on these TCR-experienced effector-ͳʹ͹ 
like CD4
+
 T cells (TEXP cells; Supplementary Fig. 2a). While IL-6 stimulation of CD4
+
 TEXP cells induced ͳʹͺ 
pY-STAT3, the activation of pY-STAT1 was minimal when compared to the IL-6-dependent induction of ͳʹͻ 
pY-STAT1 in CD4
+
 TN cells (Supplementary Fig. 2b,c), indicating CD4
+
 T cell activation altered the ͳ͵Ͳ 
subsequent activation of STAT1 by IL-6. ͳ͵ͳ 
To test if TCR signaling altered the IL-6-induced activation of STAT1, we generated CD4
+
 TEXP cells from ͳ͵ʹ 
wild-type CD4
+
 TN cells using varying concentrations of co-stimulatory CD3 (0.1-10 µg/ml) and CD28 (0.5-ͳ͵͵ 
15 µg/ml) antibodies (Supplementary Fig. 3a) and stimulated the expanded CD4+ TEXP cells with IL-6. The ͳ͵Ͷ 
IL-6-dependent induction of pY-STAT3 was not affected by differences in antibody concentration. ͳ͵ͷ 
However the suppression of pY-STAT1 in response to IL-6 was sensitive to anti-CD3 antibody treatment ͳ͵͸ 
with increasing doses of antibody leading to a repression of pY-STAT1 (Supplementary Fig. 3a). Thus, TCR ͳ͵͹ 
signaling affected the inhibition of pY-STAT1 by IL-6.  ͳ͵ͺ 
We next determined whether changes in STAT1 activation altered the transcriptional output of IL-6. CD4
+
 ͳ͵ͻ 
TN, TEXP and TEM cells were stimulated for 6 h with IL-6 followed by transcriptomic analysis. This time point ͳͶͲ 
was selected based on the temporal profile of pY-STAT1 and pY-STAT3 detection (Fig. 2a), and the ͳͶͳ 
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optimal expression of STAT-target genes (Ahr, Bcl3, Bcl6, Kat2b, Il10, Il21, Pim1, Stat3), as determined by ͳͶʹ 
Q-PCR (Supplementary Fig. 3b). CD4
+
 TN, TEXP, and TEM cells expressed a series of genes that were both ͳͶ͵ 
common (e.g., Socs1, Sbno2, Bcl6) and unique (e.g., CD4
+
 TN – Cxcr1, Tnfrsf14; CD4
+
 TEXP – Gzma, Ajuba; ͳͶͶ 
CD4
+
 TEM – Ahr, Il10, Il21) to all three CD4
+
 T cell populations (Fig. 2d and Supplementary Fig. 3c). The ͳͶͷ 
number of transcripts enhanced by IL-6 in CD4
+
 TEXP cells (236) was markedly reduced when compared to ͳͶ͸ 
the IL-6-dependent induction of transcripts in CD4
+
 TN cells (509) (Fig. 2e). The inclusion of anti-ͳͶ͹ 
CD3+CD28 co-stimulatory antibodies further suppressed the number of genes induced by IL-6 in CD4
+
 ͳͶͺ 
TEXP cells (26), indicating the capacity of TCR activation to replace the signal delivered by IL-6 (Fig. 2e and ͳͶͻ 
Supplementary Fig. 3d). Thus, IL-6 controls very distinct patterns of gene regulation in CD4
+
 TN, TEXP and ͳͷͲ 
TEM cells that may shape the functional properties of these CD4
+
 T cells. ͳͷͳ 
STAT1 phosphorylation is regulated by PTPN2  ͳͷʹ 
We next determined whether TCR activation altered the expression of genes linked with IL-6 receptor ͳͷ͵ 
signaling in CD4
+
 TN, TEXP and TEM cells. No significant differences in the expression of IL-6 receptor ͳͷͶ 
subunits (Il6ra, Il6st), Janus kinases (Jak1, Jak2, Tyk2), STATs (Stat1, Stat3, Stat5a, Stat5b) and regulators ͳͷͷ 
of IL-6 or Jak-STAT signaling (Socs1, Socs3, Pias1, Dusp2, Cish, Arid5a, Arid5b) were observed between ͳͷ͸ 
these CD4
+
 T cells (Supplementary Fig. 4a). Thus, the immediate regulation of STAT1 activity in CD4
+
 TEXP ͳͷ͹ 
cells and CD4
+
 TEM cells was not attributed to changes in the make-up of the IL-6 signaling cascade.  ͳͷͺ 
To examine how CD4
+
 T cell activation affected STAT1 signaling we assessed IL-6 responses in wild-type ͳͷͻ 
CD4
+
 TN and TEM cells using antibodies for serine phosphorylated STAT1 and STAT3 (hereafter pS-STAT1 ͳ͸Ͳ 
and pS-STAT3). Intracellular flow cytometry showed that the IL-6 activation of pS-STAT1 and pS-STAT3 ͳ͸ͳ 
was comparable in both CD4
+
 T cells (Fig. 3a). However, CD4
+
 TEM cells showed suppressed pY-STAT1 in ͳ͸ʹ 
response to IL-6 (Fig. 3a and Supplementary Fig. 1c). We therefore addressed whether protein ͳ͸͵ 
phosphatases controlled the tyrosine phosphorylation of STAT1. Treatment of CD4
+ 
TN and TEM cells with ͳ͸Ͷ 
the protein tyrosine phosphatase inhibitor sodium orthovanadate reversed the loss of pY-STAT1 ͳ͸ͷ 
activation in IL-6-stimulated CD4
+
 TEM cells (Fig. 3a). IL-6 control of pY-STAT3 was unaltered by sodium ͳ͸͸ 
orthovanadate (Fig. 3a). Analysis of Ahr, Il21, Socs3 and Stat3 expression in IL-6-treated CD4
+
 TEM cells ͳ͸͹ 
showed that the inclusion of sodium orthovanadate reduced expression of Il21 and Socs3 (Fig. 3b). Thus, ͳ͸ͺ 
protein tyrosine phosphatase activity appears integral to the IL-6 control of STAT1 in CD4
+
 TEM cells.  ͳ͸ͻ 
To identify protein tyrosine phosphatases responsible for the regulation of STAT1 in CD4
+ 
TEXP and TEM ͳ͹Ͳ 
cells we compared transcriptomic data from CD4
+ 
TN, TEXP and TEM cells activated with anti-CD3+CD28 co-ͳ͹ͳ 
stimulatory antibodies. Several protein phosphatases were more highly expressed in CD4
+ 
TEXP and TEM ͳ͹ʹ 
cells than CD4
+ 
TN cells, and included the protein tyrosine phosphatases Ptpn2 and Ptpn22 (Fig. 3c).  ͳ͹͵ 
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Flow cytometry showed that PTPN2 was more highly expressed in CD4
+ 
TEM cells than CD4
+ 
TN cells (Fig. ͳ͹Ͷ 
4a). Il6ra
-/-
 CD4
+ 
TEM cells had comparable expression of PTPN2 to wild-type CD4
+ 
TEM cells (Fig. 4b), ͳ͹ͷ 
indicating that PTPN2 expression was independent of IL-6 signaling. To confirm the relevance of these ͳ͹͸ 
findings to pathology we conducted immunohistochemistry of joint tissue from wild-type mice with AIA. ͳ͹͹ 
Synovial CD3
+
 T cells showed enhanced expression of PTPN2 and low pY-STAT1 staining (Fig. 4c). ͳ͹ͺ 
Similarly, flow cytometry of IL-6-stimulated CD4
+
 TEM cells revealed that PTPN2 expression correlated ͳ͹ͻ 
with suppression of pY-STAT1 (Fig. 4b, Supplementary Fig. 4b). We next investigated IL-6 signaling in ͳͺͲ 
CD4
+ 
TN and TEXP cells from whole genome C57Bl/6 Ptpn22
-/- 
mice and Lck-Cre Ptpn2
fl/fl 
mice, which lack ͳͺͳ 
PTPN2 in CD4
+
 T cells. As controls we used IL-6-treated CD4
+
 TN and TEXP cells isolated from C57Bl/6 wild-ͳͺʹ 
type mice (for PTPN22) or C57Bl/6 Ptpn2
fl/fl 
littermates. IL-6 activated pY-STAT1 in both Lck-Cre Ptpn2
fl/fl
 ͳͺ͵ 
and Ptpn22
-/-
 CD4
+ 
TEXP cells (Fig. 4d). When compared to IL-6 stimulated CD4
+ 
TEXP cells from Lck-Cre ͳͺͶ 
Ptpn2
fl/fl
 mice, the recovery of pY-STAT1 activity in IL-6 treated Ptpn22
-/-
 CD4
+ 
TEXP cells was less obvious ͳͺͷ 
(Fig. 4d). This possibly reflected a lower expression of Ptpn22 in CD4
+ 
TEXP cells (Fig. 3c). Thus, PTPN2 ͳͺ͸ 
acted as a repressor of IL-6-induced STAT1 tyrosine phosphorylation in activated CD4
+
 T cells. ͳͺ͹ 
We next explored whether PTP activity affected the production of IL-17A and IL-21 in CD4
+ 
TEM cells. ͳͺͺ 
Intracellular flow cytometry indicated that Lck-Cre Ptpn2
fl/fl
 and Ptpn22
-/-
 CD4
+ 
TEM cells mice generated ͳͺͻ 
less IL-17A and IL-21 than CD4
+ 
TEM cells from Ptpn2
fl/fl
 littermates or wild-type mice (Fig. 4e, ͳͻͲ 
Supplementary Fig. 4c). Moreover, ImageStream analysis showed the co-localization of PTPN2 with non-ͳͻͳ 
phosphorylated STAT1 in wild-type CD4
+ 
TEM cells (Fig. 4f). Thus, PTPN2, and to a lesser extent PTPN22, ͳͻʹ 
regulated STAT1 signaling in activated and memory CD4
+
 T cells. ͳͻ͵ 
T cell activation re-tunes the transcriptional output of IL-6 in CD4
+
 TEM cells ͳͻͶ 
Next, we compared the transcriptional output of IL-6 in CD4
+ 
TN, TEXP and TEM cells. Analysis was confined ͳͻͷ 
to significantly regulated genes (p<0.05) that displayed both a relative signal intensity of >150 and >1.5 ͳͻ͸ 
fold alteration in expression. Circos visualization identified a number of genes that were under IL-6 ͳͻ͹ 
control in CD4
+ 
TN (225), TEXP (31) and TEM (180) cells (Fig. 5a). Hierarchical clustering and validation of ͳͻͺ 
selected gene targets identified IL-6 gene signatures that were either common to all three CD4
+ 
T cells or ͳͻͻ 
uniquely expressed by a particular population (Supplementary Fig. 3c). Genes regulated by IL-6 in CD4
+ ʹͲͲ 
TN, TEXP and TEM cells were mainly STAT3 target genes
23, 24
 and included genes that encoded ʹͲͳ 
transcriptional regulators (e.g., Bcl3, Bcl6, Etv6), co-repressors (e.g., Sbno2, Muc1) and negative ʹͲʹ 
regulators (e.g., Socs3, Pim1, Batf) of transcription factors such as STAT3, NF-κB and AP1 (Supplementary ʹͲ͵ 
Fig. 3c). ʹͲͶ 
Next, we conducted a molecular pathway analysis of the transcriptomic data from IL-6-treated CD4
+ 
TN, ʹͲͷ 
TEXP and TEM cells (Fig. 5b). We also mapped these datasets against publicly-available transcriptomic data ʹͲ͸ 
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from IL-6-stimulated Stat1
-/-
 and Stat3
-/-
 CD4
+
 T cells (Fig. 5c)
20
. This analysis identified a series of STAT1-ʹͲ͹ 
regulated genes commonly associated with interferon (e.g., Irf8, Gbp2, Gbp5, Gbp6, Stat1, Parp9). In ʹͲͺ 
contrast, STAT3-regulated genes displayed greater functional diversity and were implicated in interleukin ʹͲͻ 
signaling, immune activation, proliferation, catabolism and metabolism (e.g., Socs3, Bcl3, Il6r, Kat2b) ʹͳͲ 
(Fig. 5b,c). This collective approach demonstrated that STAT1 and STAT3 regulated very distinct patterns ʹͳͳ 
of gene expression in IL-6 stimulated CD4
+ 
TN, TEXP and TEM cells (Fig. 5b,c). For example, when compared ʹͳʹ 
with IL-6 stimulated CD4
+ 
TN cells, activation with IL-6 enhanced the expression of genes associated with ʹͳ͵ 
prolonged lymphocyte survival and memory (e.g., Hmox1, Myc, Cd83), and regulatory (e.g., Lag3, Il10, ʹͳͶ 
Foxp3) or effector (e.g., Ahr, Il21, Ifng) characteristics in CD4
+ 
TEM cells.  ʹͳͷ 
We next performed ChIP-seq in IL-6-stimulated CD4
+ 
TN and TEM cells. Sequencing peaks displaying a 4-ʹͳ͸ 
fold increase above input (P<0.0001; FDR 0.05) were aligned to the genome and assigned to transcription ʹͳ͹ 
start sites (TSS), exons and introns (Fig. 6 and Supplementary Fig. 5). Peaks located in undefined ʹͳͺ 
intergenic regions were excluded from the analysis. ChIP-seq of IL-6-stimulated CD4
+ 
TN cells identified ʹͳͻ 
1625 peaks associated with STAT1 and 602 peaks for STAT3 (Fig. 6a). The number of STAT1 (446) and ʹʹͲ 
STAT3 (552) peaks was reduced in CD4
+ 
TEM cells (Fig. 6a). To understand the regulatory properties of ʹʹͳ 
STAT1 and STAT3 we first confined our analysis to peaks residing within TSS regions (Fig. 6b and ʹʹʹ 
Supplementary Fig. 5). Sequencing peaks that mapped to defined gene promoters were correlated ʹʹ͵ 
against corresponding transcriptomic data from IL-6-treated CD4
+ 
TN and TEM cells (Fig. 6c and ʹʹͶ 
Supplementary Fig. 5). STAT1 and STAT3 showed substantially reduced binding to TSS regions in CD4
+ 
TEM ʹʹͷ 
cells compared to CD4
+ 
TN cells (Fig. 6b,c,d). Very few genes shared STAT1 and STAT3 binding (e.g., Stat3, ʹʹ͸ 
Stat5b, Icam1, Socs3, Sigirr, and Akt2) (Fig. 6b,d), and these co-regulated genes were largely restricted to ʹʹ͹ 
CD4
+ 
TN cells (Fig 6b,d). Stat3 was the only gene that was bound by both STAT1 and STAT3 in CD4
+ 
TEM ʹʹͺ 
cells (Fig. 6c). To determine the specificity of these DNA-transcription factor interactions we used ʹʹͻ 
computational tools to identify consensus DNA motifs for STAT1 and STAT3 binding (Supplementary Fig. ʹ͵Ͳ 
5c). Analysis of ChIP-seq datasets from IL-6-treated CD4
+ 
TN and TEM cells identified sequences resembling ʹ͵ͳ 
an IFN-regulated STAT responsive element (ISRE; E-value 5.9e-040) for STAT1 binding, and sequences ʹ͵ʹ 
homologous to a gamma-activated sequence (GAS; E-value 1.2e-115) for STAT3 (Supplementary Fig. 5c). ʹ͵͵ 
We also identified consensus motifs for other transcription factors including SP1 and C2H2 Zn-finger ʹ͵Ͷ 
transcription factor proteins (Supplementary Fig. 5c) and ChIP-qPCR showed STAT1 and STAT3 bound to ʹ͵ͷ 
SP1 consensus binding sequences (Supplementary Fig. 5d and Supplementary Table 2). Thus, ʹ͵͸ 
transcriptional differences between IL-6 stimulated CD4
+ 
TN and TEM cells are shaped by STAT1 and STAT3 ʹ͵͹ 
docking to both classical STAT-responsive elements and DNA motifs that suggested a regulatory interplay ʹ͵ͺ 
with other transcription factors in CD4
+ 
TN and TEM cells. ʹ͵ͻ 
Genes under IL-6 control in CD4
+ 
TEM cells are regulated at distal promoter regions  ʹͶͲ 
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Next we investigated the canonical pathways associated with the genes that were bound with STAT1 or ʹͶͳ 
STAT3 in IL-6-treated CD4
+ 
TN and TEM cells. Bioinformatic analysis identified a selective enrichment of ʹͶʹ 
genes involved in disease processes, catabolism and cytokine signaling in CD4
+ 
TEM cells as compared to ʹͶ͵ 
CD4
+ 
TN cells (Supplementary Fig. 6a and Supplementary Table 3). Many of the genes associated with ʹͶͶ 
these pathways were distinct from those showing STAT1 or STAT3 binding to TSS (Fig. 6b), suggesting ʹͶͷ 
that genes under IL-6 regulation in CD4
+ 
TEM cells may be controlled by STAT1 and STAT3 binding to distal ʹͶ͸ 
promoter regions. To identify possible mechanisms that may explain this distal regulation we evaluated ʹͶ͹ 
whether STAT1 and STAT3 peaks aligned with enhancer regions displaying enriched binding of the ʹͶͺ 
histone acetyl-transferase P300 (hereafter P300 enhancer elements
25, 26, 27, 28
). STAT1 and STAT3 ChIP-seq ʹͶͻ 
datasets from IL-6-treated CD4
+ 
TN or TEM cells were mapped against publicly-available P300 ChIP-seq ʹͷͲ 
data from mouse CD4
+
 T cells polarized in vitro into TH1, TH2 or TH17 cells
28
 (Supplementary Fig. 6b and ʹͷͳ 
Supplementary Table 4). A combined analysis of IL-6-treated CD4
+ 
TN and TEM cells identified 558 genes ʹͷʹ 
that bound P300 in association with either STAT1 or STAT3 (Fig. 7a,b). In IL-6-stimulated CD4
+ 
TN and TEM ʹͷ͵ 
cells we identified 215 genes that displayed alternate binding of STAT1 or STAT3 in CD4
+ 
TN and TEM cells ʹͷͶ 
(Fig. 7b). These genes were selectively induced or repressed by IL-6 in CD4
+ 
TEM cells (Fig. 7b, ʹͷͷ 
Supplementary Table 5). Among these, 208 genes aligned with genes bound by P300 in TH17 cells
28
. ʹͷ͸ 
These included genes linked with proliferation and survival (e.g., Vmp1, Rbpj, Fasl), immune regulation ʹͷ͹ 
(e.g., Cd200, Cish, Ctla4, Cd69), alternate lineage fates (e.g., Ahr, Batf, Bcl6, Cxcr5, Etv6, Fosl2, Irf4, Stat3) ʹͷͺ 
or differences in T cell effector function (e.g., Il10, Il21, Il4ra, Il17a, Il17ra, Il21r) (Supplementary Table 5). ʹͷͻ 
This analysis indicated that genes controlled by IL-6 in CD4
+ 
TN and TEM cells are associated with P300 ʹ͸Ͳ 
enhancer elements that are potentially activated or suppressed by changes in the pattern of STAT1 or ʹ͸ͳ 
STAT3 binding. ʹ͸ʹ 
Among the 215 genes regulated by IL-6 in CD4
+ 
TEM cells, 80 displayed STAT1 or STAT3 binding in ChIP-seq ʹ͸͵ 
data from IL-6 activated CD4
+ 
TN cells, but not in IL-6 treated CD4
+ 
TEM cells (Fig. 7c). This suggested that ʹ͸Ͷ 
the binding of these transcription factors to these sites acted as repressors of gene activation. ChIP-seq ʹ͸ͷ 
analysis of the other 135 genes showed that some form of STAT1 or STAT3 binding to P300 enhancer ʹ͸͸ 
elements was retained in both IL-6 stimulated CD4
+ 
TN and TEM cells (Fig. 7c and Supplementary Fig. 6b). ʹ͸͹ 
These included Il10, Il21, Il21r, Bcl3, Batf, Junb, Socs1 and Cd274 (Fig.7c). Circos visualization illustrated ʹ͸ͺ 
how the binding of STAT1 and STAT3 to these promoters differed between IL-6 stimulated CD4
+ 
TN and ʹ͸ͻ 
TEM cells (Fig. 7c). We identified 5 discrete patterns of STAT1 and STAT3 binding – pattern 1 (CD4
+ 
TN cells: ʹ͹Ͳ 
no STAT binding; TEM cells: STAT1), pattern 2 (CD4
+ 
TN cells: STAT1, STAT3; TEM cells: STAT3), pattern 3 ʹ͹ͳ 
(CD4
+ 
TN cells: STAT3; TEM cells: STAT3), pattern 4 (CD4
+ 
TN cells: STAT1; TEM cells: STAT3) and pattern 5 ʹ͹ʹ 
(CD4
+ 
TN cells: no STAT binding; TEM cells: STAT3) (Fig.7d). Computational analysis of the genes affiliated ʹ͹͵ 
to each pattern revealed links with the cytokine control of T cell proliferation, differentiation and survival ʹ͹Ͷ 
(Fig. 7d, Supplementary Fig. 6b and Supplementary Table 6). This was particularly apparent in pattern 2, ʹ͹ͷ 
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and to a lesser extent, pattern 3 and 5. Promoter regions assigned to pattern 2 displayed binding of ʹ͹͸ 
STAT1 and STAT3 in IL-6 stimulated CD4
+ 
TN cells, but showed a loss of STAT1 in IL-6 activated CD4
+ 
TEM ʹ͹͹ 
cells. Genes identified with this form of STAT regulation included Junb, Il4ra, Cd274 and Socs1 (Fig.7c and ʹ͹ͺ 
Supplementary Fig.6b) and suggested a potential link to the PTPN2-regulated of pY-STAT1. We therefore ʹ͹ͻ 
conducted a ChIP-qPCR analysis of STAT1 binding to the promoters of Junb, Il4ra, Cd274 and Socs1 in ʹͺͲ 
IL-6-stimulated Lck-Cre Ptpn2
fl/fl
 and Ptpn2
fl/fl
 CD4
+ 
TEM cells. STAT1 binding to these promoters was ʹͺͳ 
specifically enriched in DNA samples from Lck-Cre Ptpn2
fl/fl
CD4
+
 TEM cells as compared to control Ptpn2
fl/fl
 ʹͺʹ 
CD4
+ 
TEM cells (Fig. 7e). In contrast, the binding of STAT1 to the TSS regions of Stat3 and Irf1 remained ʹͺ͵ 
unaltered, and DNA samples from Lck-Cre Ptpn2
fl/fl
CD4
+
 TEM cells and control Ptpn2
fl/fl
 CD4
+ 
TEM cells ʹͺͶ 
showed similar enrichment for STAT1 (Fig. 7e). Thus, PTPN2 activity determined STAT1 binding to specific ʹͺͷ 
gene promoter regions in IL-6 activated CD4
+ 
TEM cells. ʹͺ͸ 
PTPN2 correlates with indices of synovial pathology in rheumatoid arthritis patients  ʹͺ͹ 
Many of the genes identified in IL-6 stimulated CD4
+ 
TEM cells contribute to the generation and ʹͺͺ 
maintenance of effector T cells associated with autoimmunity (Supplementary Table 6). We therefore ʹͺͻ 
investigated the relationship between PTPN2 and PTPN22 and these IL-6-regulated genes in RNA-seq ʹͻͲ 
datasets from synovial tissues biopsies of 87 patients with rheumatoid arthritis. Expression of PTPN2 and ʹͻͳ 
PTPN22 in these biopsy samples was compared against corresponding histological staining of the ʹͻʹ 
inflamed synovium for the lymphocyte markers CD3 and CD20 by immunohistochemistry. Analysis ʹͻ͵ 
revealed a close correlation between PTPN2 and CD3 and CD20 (Fig 8a). This association was particularly ʹͻͶ 
evident in synovial biopsies displaying evidence of ectopic lymphoid-like structures (lymphoid-rich) and ʹͻͷ 
synovitis with a prominent mononuclear cell infiltrate (myeloid-rich) (Fig. 8b)
29
. In contrast, PTPN22 ʹͻ͸ 
displayed a more uniform pattern of expression within the inflamed synovium and showed no ʹͻ͹ 
correlation with lymphocyte markers or the type of synovial pathology (Fig. 8a,b). To establish a possible ʹͻͺ 
link between PTPN2 and the synovial expression of genes controlled by IL-6 in activated or memory CD4
+ ʹͻͻ 
T cells PTPN2 was compared against the synovial expression of IL21, IL17A, CD274 and SOCS1. Analysis of ͵ͲͲ 
synovial RNA-seq datasets showed a correlation between PTPN2 and IL21, IL17A, CD274 and SOCS1 (Fig. ͵Ͳͳ 
8c). This relationship was particularly evident in both lymphoid-rich and myeloid-rich synovitis (Fig. 8c). ͵Ͳʹ 
No clear correlation was observed between PTPN22 and these inflammatory markers (Fig. 8c). Thus, in ͵Ͳ͵ 
human synovial pathology, PTPN2 associates with the involvement of lymphocytes in the disease process ͵ͲͶ 
and corresponds with the expression of several inflammatory mediators linked to the regulation of ͵Ͳͷ 
STAT1 by PTP enzymes.   ͵Ͳ͸ 
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Discussion ͵Ͳ͹ 
Through analysis of Jak-STAT signalling in CD4
+ 
TN and TEM cells we identified that protein tyrosine ͵Ͳͺ 
phosphatases induced as a response to CD4
+ 
TN cell activation altered the transcriptional output of IL-6 in ͵Ͳͻ 
CD4
+ 
TEM cells. Our investigation showed that inhibition of STAT1 phosphorylation by PTPN2 affected the ͵ͳͲ 
expression of certain STAT-regulated target genes in activated or memory CD4
+
 T cells. Thus, protein ͵ͳͳ 
tyrosine phosphatases have the capacity to modify the way particular T cell subsets sense and interpret ͵ͳʹ 
common cytokine cues. Whilst the study focussed on the biology of IL-6, this mechanism may also shape ͵ͳ͵ 
the transcriptional output of other lymphokines in CD4
+
 T cells. ͵ͳͶ 
Protein phosphatases including dual specificity protein phosphatases (DUSP) and protein tyrosine ͵ͳͷ 
phosphatases (PTP) can regulate Jak-STAT signaling
30, 31
. For example, PTPN2 and PTPN11 control the ͵ͳ͸ 
phosphorylation of STAT1 in fibroblasts
32, 33
. We showed that protein tyrosine phosphatases restrained ͵ͳ͹ 
IL-6 signaling through STAT1 in activated and memory CD4
+
 T cells. Transcriptional profiling of PTP ͵ͳͺ 
expression in CD4
+
 T cells identified several candidate enzymes that were induced following CD4
+ 
TN ͵ͳͻ 
activation, including PTPN2, PTPN22 and DUSP2. Because DUSP2 inhibits signaling through STAT3 and ͵ʹͲ 
restricts TH17 differentiation
30
, we assessed whether PTPN2 and PTPN22 affected STAT1 ͵ʹͳ 
phosphorylation. PTPN2 and PTPN22 inhibited STAT1 activity, but had a less obvious impact on STAT3 ͵ʹʹ 
activity. This observation might indicate a physical interaction between these PTP and STAT1.   ͵ʹ͵ 
PTPN2 and PTPN22 control various lymphocyte responses, and individuals with genetic polymorphisms ͵ʹͶ 
in PTPN2 or PTPN22 frequently show increased susceptibility to autoimmune disease
34, 35
. The ability of ͵ʹͷ 
PTPN2 and PTPN22 to control Jak-STAT signaling may contribute to these outcomes through the control ͵ʹ͸ 
of immune activation, tolerance and autoimmunity. Our data showed that synovial PTPN2 was highly ͵ʹ͹ 
expressed in lymphoid-rich synovitis. This form of joint pathology is defined by the presence of ͵ʹͺ 
functional ectopic lymphoid aggregates within the inflamed synovium
36
. Significantly, PTPN2 has been ͵ʹͻ 
linked with the regulation of follicular TH cells and the activation of T and B cell responses
37, 38, 39, 40
. Our ͵͵Ͳ 
investigation showed that PTPN2 controlled the expression of genes commonly associated with ectopic ͵͵ͳ 
lymphoid-like structures. For example, PTPN2-control of STAT1 phosphorylation was shown to affect the ͵͵ʹ 
transactivation of inflammatory cytokines (e.g., IL-17A, IL-21), transcription factors (e.g., Bcl6), immune ͵͵͵ 
checkpoint regulators (e.g., CD274) and homeostatic chemokine receptors (e.g., CXCR4, CXCR5) involved ͵͵Ͷ 
in the activity or spatial organization of lymphoid aggregates
36
. The gene signature identified through our ͵͵ͷ 
screen may therefore predict the efficacy of adoptive immunotherapy and vaccination strategies, or ͵͵͸ 
response to biological drug therapies. ͵͵͹ 
ChIP-seq of STAT1 and STAT3 in IL-6-treated CD4
+ 
TN and TEM cells showed that both transcription factors ͵͵ͺ 
bound to consensus motifs for STAT proteins (e.g., ISRE, GAS), and sequences specific for other ͵͵ͻ 
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transcription factors (e.g., SP1-like proteins)
41, 42, 43, 44
. While the binding of STATs to these genomic sites ͵ͶͲ 
requires further analysis, our results suggested that the induction of PTPN2 in activated CD4
+
 T cells ͵Ͷͳ 
affected the expression of STAT-regulated genes controlled by P300 enhancer elements. Many of the ͵Ͷʹ 
genes associated with these enhancers were induced by IL-6 in CD4
+ 
TEM cells and included genes ͵Ͷ͵ 
commonly associated with TH1, TH2, TH17 or TFH cells
27, 28
. These activities fit with the capacity of IL-6 to ͵ͶͶ 
govern CD4
+ 
T cell memory
4, 5, 45, 46
. For example, IL-6 renders antigen-specific T cells refractory to ͵Ͷͷ 
suppression by regulatory T cells
56, 57
. However, IL-6 signaling is not critical for the generation or ͵Ͷ͸ 
maintenance of CD4
+
 memory cells
4, 6
. Instead, our data revealed that IL-6 promotes the effector or ͵Ͷ͹ 
functional characteristics of CD4
+ 
TEM cells. This contrasts with the activities of IL-23, which regulates ͵Ͷͺ 
memory recall through the control of cell-cycle progression and proliferation
7, 47, 48
. Thus, PTPN2 control ͵Ͷͻ 
of STAT1 may support CD4
+
 T cell memory responses by shaping effector memory functions or ͵ͷͲ 
prolonging lymphocyte survival. Such findings may be relevant to our understanding of how T cells ͵ͷͳ 
become released from anergy and might explain how T cells become directed down a commitment ͵ͷʹ 
pathway as a response to specific TCR antigens
39, 49, 50
.  ͵ͷ͵ 
  ͵ͷͶ 
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Figure Legends- ͷͶͲ 
Figure 1. Infiltrating T-cells showed impaired STAT1 activity in response to arthritis induction. (a) ͷͶͳ 
Representative H&E staining of knee joints at day 10 post disease induction (antigen-induced arthritis, ͷͶʹ 
AIA) (bar: 500µm); boxed area shows the location of the immunofluorescence. Representative ͷͶ͵ 
immunofluorescence with antibodies against CD3 (red), pY-STAT1 or pY-STAT3 (green) is shown together ͷͶͶ 
with DAPI counterstaining (blue) (bar: 100µm). Graph shows the proportion of CD3+ T cells displaying ͷͶͷ 
either pY-STAT1 or pY-STAT3 (n=3). (b) Phosphorylation of STAT1 and STAT3 by flow cytometry of ͷͶ͸ 
infiltrating synovial CD4
+ 
T cells during AIA after stimulation with 20ng/ml IL-6 compare to CD4
+
 TN cells. ͷͶ͹ 
(c) Representative flow cytometry of pY-STAT1 and pY-STAT3 in CD4
+
 T cells extracted from inguinal ͷͶͺ 
lymph nodes of mBSA challenged (n=4) and non-challenged mice (control) (n=3) following stimulation ͷͶͻ 
with 20ng/ml IL-6 for 30 min. Graphs show quantification of pY-STAT1 and pY-STAT3 activity in CD4
+
 TN ͷͷͲ 
and CD4
+
 TEM cells (n=4). (d) Quantitative PCR of Ahr, Ifng, Il17a, Il21, Rorc, Socs3 and Stat3 in CD4
+
 TN ͷͷͳ 
(n=4) and CD4
+
 TEM cells (n=2) extracted from inguinal lymph nodes of mBSA challenged mice. (e) ͷͷʹ 
Intracellular flow cytometry analysis of IL-21 production in CD4
+
 TN and CD4
+
 TEM cells extracted from ͷͷ͵ 
inguinal lymph nodes after 4 hours stimulation with PMA, ionomycin and monensin (n=4). Data are ͷͷͶ 
representative of three independent experiments (c,e), two independent experiments (a,b) and one ͷͷͷ 
experiment involving biological replicates (d). ****P<0.0001, **P<0.01, *P<0.05 (Two-tailed unpaired ͷͷ͸ 
Student’s t test (a,b,d,e) and one-way ANOVA test with Tukey's multiple comparison test (c). Data are ͷͷ͹ 
shown as mean ± s.d.)  ͷͷͺ 
 ͷͷͻ 
Figure 2. CD4
+
 T cell subsets show different response to IL-6. (a) Representative flow cytometry analysis ͷ͸Ͳ 
of STAT1 and STAT3 responses in naïve (TN), central memory (TCM), effector (TEff) and effector memory ͷ͸ͳ 
(TEM) CD4
+
 T cells after 30 min IL-6 stimulation (20ng/ml). Numbers indicate the percentage of pY-STAT1 ͷ͸ʹ 
or pY-STAT3 staining. Temporal changes in pY-STAT1 and pY-STAT3 are shown for each T cell subset ͷ͸͵ 
following IL-6 stimulation (n=3). (b) Detection of pY-STAT1 and pY-STAT3 in CD4
+
 TN, CD4
+
 TCM, CD4
+
 TEff ͷ͸Ͷ 
and CD4
+
 TEM cells from WT and IL6ra
-/-
 mice. CD4
+
 T cells were stimulated for 30 min with an equimolar ͷ͸ͷ 
concentration of IL-6 or an IL-6-sIL-6R fusion protein (HDS) (n=3). (c) Intracellular flow cytometry analysis ͷ͸͸ 
of pY-STAT1 in CD4
+
 T cells following 30 min stimulation with IL-6, IL-27 or IFNγ (20ng/ml) (n=3). (d) ͷ͸͹ 
Microarray expression data is presented for CD4
+
 TN (n=3), CD4
+
 TEM (n=3), and in vitro expanded CD4
+
 ͷ͸ͺ 
effector-like T cells (See Supplementary Fig.2a, CD4
+
 TEXP) (n=4) treated with 20ng/ml IL-6 for 6 hours. ͷ͸ͻ 
Analysis was confined to genes displaying both a relative signal intensity of >150 and >1.5-fold alteration ͷ͹Ͳ 
in expression following IL-6 treatment (P<0.05). Heat map is hierarchically clustered based in the relative ͷ͹ͳ 
expression (Z-score) (left panel) or Fold change (right panel). (e) Volcano plots displaying IL-6 regulated ͷ͹ʹ 
gene expression in CD4
+
 TN and CD4
+
 TEXP cells stimulated with IL-6 (20ng/ml) or in combination with ͷ͹͵ 
antibodies against CD3 and CD28. An interactive figure can be found on-line (http://jones-ͷ͹Ͷ 
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cytokinelab.co.uk/NI2019/figure2d.shtml). Data are representative of two independent experiments ͷ͹ͷ 
(a,c) and one experiment involving biological replicates (b,d,e). ***P<0.001 *P<0.05 (Two-tailed unpaired ͷ͹͸ 
Student’s t test (a) and one-way ANOVA with Tukey's multiple comparison test (b,c). Data are shown as ͷ͹͹ 
mean ± s.e.m). ͷ͹ͺ 
 ͷ͹ͻ 
Figure 3. Induction of protein tyrosine phosphatases following T-cell activation limits STAT1 signalling. ͷͺͲ 
(a) CD4
+
 TN and CD4
+
 TEM cells were pre-treated for 5 min with 5mM sodium orthovanadate (vanadate) ͷͺͳ 
prior to IL-6 (20ng/ml) stimulation for 30 min. Changes in pY-STAT1 and pY-STAT3 activity were ͷͺʹ 
monitored by intracellular flow cytometry (MFI). A comparable analysis of pS-STAT1 and pS-STAT3 is ͷͺ͵ 
shown as a control (n=3). (b) Quantitative PCR for Ahr, Il21, Stat3 and Socs3 after vanadate pre-ͷͺͶ 
treatment and 20ng/ml IL-6 stimulation in CD4
+
 TEM cells (n=3). (c) Heatmap analysis of Affymetrix ͷͺͷ 
transcriptomic data identifies the top 20 genes (P<0.05; relative signal intensity of >150; 1.5-fold ͷͺ͸ 
alteration) associated with protein tyrosine phosphatase enzyme family. Data is presented as a ͷͺ͹ 
hierarchical cluster using the average linkage method (row 1-pearson rank correlation). Data are ͷͺͺ 
representative of two independent experiment (a,b) and one experiment involving biological replicates ͷͺͻ 
(c). ***P<0.001; ** P<0.01 (one-way ANOVA with Tukey's multiple comparison test (a) and two-way ͷͻͲ 
ANOVA with Sidak multiple comparison test (b). Data are shown as mean ± s.e.m (a) and mean ± s.d (b). ͷͻͳ 
 ͷͻʹ 
Figure 4. STAT1 activity is regulated by PTPN2. (a) Representative histogram of PTPN2 staining in CD4
+
 ͷͻ͵ 
TN and CD4
+
 TEM cells by flow cytometry. (b) Flow cytometry analysis of STAT1 phosphorylation and ͷͻͶ 
PTPN2 expression in CD4
+
 TN and CD4
+
 TEM cells analyzed 30 min after stimulation with 20 ng/ml IL-6. (c) ͷͻͷ 
Immunohistochemistry of the inflamed synovium from wild-type mice with antigen-induced arthritis ͷͻ͸ 
(day-10 post disease induction) in tissue sections stained with antibodies against CD3, Ptpn2 and ͷͻ͹ 
pY-STAT1. Scale bar, 100µm (left panel) and 200µm (right panel). (d) Analysis of pY-STAT1 and pY-STAT3 ͷͻͺ 
in CD4
+
 TN and CD4
+
 TEXP cells derived from Ptpn2
fl/fl
, Lck-Cre Ptpn2
fl/fl 
(left panel) or wild-type and ͷͻͻ 
Ptpn22
-/-
 mice (right panel) (n=4) exposed to IL-6 (20 ng/ml) for 30 min in combination with antibodies ͸ͲͲ 
against CD3 and CD28. Fold change relative to the untreated controls are compared. (e) IL-21 and IL-17A ͸Ͳͳ 
quantification by flow cytometry in CD4
+
 TEM cells from Ptpn2
fl/fl 
and Lck-Cre Ptpn2
fl/fl 
mice (n=3). (f) ͸Ͳʹ 
ImageStream analysis of STAT1 and PTPN2 localization in CD4
+
 TN and CD4
+
 TEM cells stained with ͸Ͳ͵ 
antibodies against STAT1, pY-STAT1, PTPN2 and CD4. Data are representative of three independent ͸ͲͶ 
experiments (a,b), two independent experiments (f) and one experiment involving biological replicates ͸Ͳͷ 
(c,d,e). ****P<0.0001; *** P<0.001 (One-way ANOVA with Tukey's multiple comparison test (d) and ͸Ͳ͸ 
Two-tailed unpaired Student’s test (e). Data are shown as mean ± s.d.).  ͸Ͳ͹ 
 ͸Ͳͺ 
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Figure 5. Transcriptomic analysis of IL-6 responses in CD4
+
 T cells. (a) Circos visualisation details the IL-6 ͸Ͳͻ 
regulated gene changes in CD4
+
 TN and CD4
+
 TEXP cells (See Supplemental Figure-2), and ex vivo sorted ͸ͳͲ 
CD4
+
 TEM cells. Total number of IL-6 regulated genes is presented in parenthesis for each population (P< ͸ͳͳ 
0.05, Chip Intensity 150+, and > 1.5-fold change). Lines coloured in red represent up-regulated genes and ͸ͳʹ 
all down-regulated gene changes are blue. Connecting lines highlight common genes that are IL-6 ͸ͳ͵ 
regulated in two or more of the populations. (b) IPA analysis of genes associated with IL-6, STAT1 and ͸ͳͶ 
STAT3 upstream regulators. Top left heat map shows the predicted activated state (orange) and the ͸ͳͷ 
predicted inhibited state (blue) of transcription regulators. Upstream regulator analysis for CTLA4 and ͸ͳ͸ 
CD3 are presented as controls. Relative expression heat maps are presented as a hierarchical cluster ͸ͳ͹ 
using the average linkage method (row 1-pearson rank correlation). The differential expression of genes ͸ͳͺ 
being regulated by IL-6, STAT1 or STAT3 is shown for CD4
+
 TN, CD4
+
 TEXP and CD4
+
 TEM cells. (c) IL-6 ͸ͳͻ 
regulated gene changes derived from transcriptomic analysis were directly compared with datasets ͸ʹͲ 
derived from IL-6 stimulated Stat1
-/- 
and Stat3
-/-
 CD4
+
 T cells (GSE65621).  ͸ʹͳ 
 ͸ʹʹ 
Figure 6. ChIP-seq analysis of STAT1 and STAT3 binding in IL-6 stimulated CD4
+
 T cells. ChIP-seq was ͸ʹ͵ 
performed on genomic DNA extracted from sorted CD4
+
 TN and CD4
+
 TEM cells following 1-hour ͸ʹͶ 
stimulation with IL-6 in presence of antibodies against CD3 and CD28. Peak calling and downstream data ͸ʹͷ 
processing are described in Materials & Methods. (a) Pie charts show the proportion of peaks associated ͸ʹ͸ 
with STAT1 and STAT3 binding to defined genomic regions. The total number of peaks identified is ͸ʹ͹ 
displayed graphically. All datasets residing outside TSS regions were only included if located to exonic or ͸ʹͺ 
intronic sites. (b) Analysis of gene clusters regulated by binding STAT1 and STAT3 in TSS promoter ͸ʹͻ 
regions. The heat map shows the score value for each gene identified with Homer for STAT1 and STAT3 ͸͵Ͳ 
ChIP-seq data in CD4
+
 TN (blue) and CD4
+
 TEM (red) cells. (c) Comparison of ChIP-seq datasets against ͸͵ͳ 
Affymetrix gene expression (relative significance; -(log10 (adjusted P-value)). Analysis of STAT1 and ͸͵ʹ 
STAT3 datasets is shown for CD4
+
 TN (blue) and CD4
+
 TEM (red) subsets. An interactive figure of additional ͸͵͵ 
information can be found on-line (http://jones-cytokinelab.co.uk/NI2019/figure6c.shtml) (d) Circos ͸͵Ͷ 
visualization of STAT1 and STAT3 binding to TSS regions of genes under IL-6 regulation in CD4
+
 TN and ͸͵ͷ 
CD4
+
 TEM cells. Connecting lines are color coded to reflect involvement of STAT1 (green), STAT3 (blue) or ͸͵͸ 
both STAT1 and STAT3 (orange). ͸͵͹ 
    ͸͵ͺ 
Figure 7. IL-6 regulates the interaction of STAT1 and STAT3 with P300 enhancer sites. (a) Circos plot ͸͵ͻ 
shows the co-localisation of STAT1 (blue) and STAT3 (orange) binding to genomic regions sharing P300 ͸ͶͲ 
enrichment in CD4
+
 TN and CD4
+
 TEM cells. The connecting lines show the relationship of STAT1 and STAT3 ͸Ͷͳ 
binding between CD4
+
 TN and CD4
+
 TEM cells. P300 ChIP-seq datasets (Accession number GSE40463, ͸Ͷʹ 
GSE60482) are derived from TH1, TH2 and TH17 cells. (b) Heat map showing the expression of all IL-6 ͸Ͷ͵ 
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regulated genes linked with P300 binding in CD4
+
 TN and CD4
+
 TEM cells (positioned left). The ͸ͶͶ 
correspondingly aligned heatmap (positioned right) shows the relationship to P300 sites in TH1, TH2 and ͸Ͷͷ 
TH17 cells and shows the number of clustered P300 sites affiliated to an individual gene (blue=0, ͸Ͷ͸ 
yellow=4). Specific examples of individual genes are shown. (c) Circos visualisation of 135 genes that ͸Ͷ͹ 
display P300 binding in association with either STAT1 or STAT3 in CD4
+
 TN versus CD4
+
 TEM cells. (d) IPA ͸Ͷͺ 
predictions of the five distinct patterns of STAT binding identified from panel c. Hierarchical clustering of ͸Ͷͻ 
canonical pathways was performed using -Log (P-value). Supplemental Table 6 lists the canonical ͸ͷͲ 
pathways represented in the heatmap. (e) STAT1 binding enrichment quantification by ChIP-qPCR in ͸ͷͳ 
Ptpn2
fl/fl
 and Lck-Cre:Ptpn2
fl/fl
 CD4
+
 TEM cells (one experiment with pool samples from 12 Ptpn2
fl/fl
 and 8 ͸ͷʹ 
Lck-Cre Ptpn2
fl/fl
 mice). ͸ͷ͵ 
 ͸ͷͶ 
Figure 8. Association of PTPN2 with rheumatoid arthritis. (a) Correlations of PTPN2 and PTPN22 with ͸ͷͷ 
lymphocyte cell markers CD3 and CD20 (left). (b) Distribution of PTPN2 and PTPN22 in patients stratified ͸ͷ͸ 
according synovial pathology (lymphoid – blue, myeloid – red and fibroid – green) (right). (c) Pearson ͸ͷ͹ 
correlations of synovium PTPN2 and PTPN22 with inflammatory markers including IL21, IL17A, CD274 ͸ͷͺ 
and SOCS1 in lymphoid (blue), myeloid (red) and fibroid (green) phenotypes. P values were adjusted ͸ͷͻ 
using false discovery rate (FDR) correction (Benjamini-Hochberg). ͸͸Ͳ 
  ͸͸ͳ 
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Materials and methods- ͸͸ʹ 
Recombinant Cytokines- Recombinant mouse IL-6 (IL-6), IL-27, IL-10, IL-7 and IFNγ were purchased from ͸͸͵ 
R&D Systems. The IL-6-sIL-6R fusion protein HDS (Mw: 63.5kDa) was expressed in CHO cells and purified ͸͸Ͷ 
through a partnership with the CRO Biovian OY (Turku, Finland). HDS was engineered by coupling the ͸͸ͷ 
entire coding sequence (amino acid residues 1-364) for the differentially-spliced variant of human IL-6R ͸͸͸ 
(containing the unique COOH-terminal amino acid sequence: GSRRRGSCGL) to IL-6 (amino acid residues ͸͸͹ 
29-212) via a flexible glycine-serine rich linker sequence (single amino sequence: GGGGSGGGGSLE)
8
.  ͸͸ͺ 
Antibodies- Mouse specific antibodies against CD3ε/γ (17A2; Biolegend), CD4 (RM4-5; eBioscience), ͸͸ͻ 
CD25 (PC61.5; eBioscience), CD44 (IM7; BD Biosciences), CD62L (MEL-14; Life Technologies), CD126 ͸͹Ͳ 
(D7715A7; eBioscience), CD127 (25-1271-82; eBioscience), βTCR (H57-597), gp130 (125623; R&D ͸͹ͳ 
Systems), IFNγ (XMG1.2; eBioscience), IL-4 (11B11; eBioscience), IL-17A (TC11-18H10.1; Biolegend), IL-21 ͸͹ʹ 
(Recombinant mouse IL-21R Fc Chimera protein; R&D and IL-21 receptor antibody; Jackson Immuno ͸͹͵ 
Research) and PTPN2 (AF1930; R&D) were used. For detection of human antigens, we used antibodies ͸͹Ͷ 
specific to CD3 (UCHT1; BioLegend), CD4 (RPA-T4; eBioscience), CD45RA (HI100; BioLegend), CD45RO ͸͹ͷ 
(UCHL1; BioLegend), CD62L (DREG-56; BD Biosciences), CD197 (CCR7; G043H7; BioLegend). Human and ͸͹͸ 
mouse cross-specific antibodies to pY-STAT1 (pY701; 4a), pY-STAT3 (pY705; 4/P-STAT3), pS-STAT1 ͸͹͹ 
(pS727; K51-856) and pS-STAT3 (pS727, 49/p-Stat3) were from BD Biosciences.  ͸͹ͺ 
Mice- Inbred wild type C57BL/6 male mice were purchased from Charles River UK. C57BL/6 IL-6 receptor ͸͹ͻ 
deficient mice (Cd126
-/-
) mice have been described previously and were bred under approved UK Home ͸ͺͲ 
Office guidelines in Cardiff University
7
. Ptpn2
fl/fl
, Lck-Cre:Ptpn2
fl/fl
, and Ptpn22
-/-
 mice were bred and ͸ͺͳ 
housed at the Peter MacCallum Cancer Centre (Melbourne, Australia). All mice were 8-12 weeks of age. ͸ͺʹ 
For T cell stimulation experiments eight-week-old male Lck-Cre;Ptpn2
fl/fl 
mice and Ptpn2
fl/fl
 littermate ͸ͺ͵ 
controls were used
38
. All procedures were performed in accordance with the NHMRC Australian Code of ͸ͺͶ 
Practice for the Care and Use of Animals, and approved by the Peter MacCallum Animal Ethics and ͸ͺͷ 
Experimentation Committee (Ethics number: AEEC 570). Antigen-induced arthritis was performed under ͸ͺ͸ 
the UK Home Office-approved project licences PPL 30/2928 and PB3E4EE13 as previously described
51
. ͸ͺ͹ 
Briefly, mice were immunized (s.c.) with 100 µl mBSA (1 mg/ml emulsified in Complete Freund’s ͸ͺͺ 
Adjuvant; CFA) and 160 ng Bordetella pertussis toxin (i.p.) (all from Sigma-Aldrich). Mice were ͸ͺͻ 
administered with mBSA and CFA (s.c.) one week later. Inflammatory arthritis was triggered 21 days ͸ͻͲ 
following the initial immunization by intra-articular administration of mBSA (10 µl; 10 mg/ml) into the ͸ͻͳ 
right knee joint. Animals were monitored daily for wellbeing and clinical signs of arthritis, and killed at ͸ͻʹ 
indicated time points for evaluation of joint-infiltrating T cells by flow cytometry and ͸ͻ͵ 
immunofluorescence. For flow cytometric analysis of synovial CD4
+ 
T cells, inflamed synovium was first ͸ͻͶ 
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dissected and digested in Collagenase type IV (37˚C, 1 hour) before passing through a 40µm cell strainer ͸ͻͷ 
to generate single cell suspensions.  ͸ͻ͸ 
Human synovial samples- Synovial samples were acquired through a minimally invasive ultrasound-͸ͻ͹ 
guided synovial biopsy (see Reference
52
) from 87 patients presenting with early rheumatoid arthritis (RA) ͸ͻͺ 
naïve to therapy from the Pathobiology of Early Arthritis Cohort (PEAC). Ethical approval was granted by ͸ͻͻ 
the King's College Hospital Research Ethics Committee (REC 05/Q0703/198). Paraffin embedded sections ͹ͲͲ 
(3μm) of each biopsy was stained with haematoxylin and eosin. Immune cell infiltration was determined ͹Ͳͳ 
in sequentially cut sections by staining for B-cells (CD20), T cells (CD3), macrophages (CD68) and plasma ͹Ͳʹ 
cells (CD138) as previously reported, categorising samples into Lympho-myeloid, Diffuse-Myeloid and ͹Ͳ͵ 
Pauci-immune Fibroid pathotypes
53
. ͹ͲͶ 
CD4
+
 T cell cultures- Murine CD4
+
 T cells were enriched by negative magnetic selection (Miltenyi Biotec) ͹Ͳͷ 
before purification of naïve (CD4
+
CD25
−
CD44
lo
CD62L
hi
CD127
hi
), central memory ͹Ͳ͸ 
(CD4
+
CD25
−
CD44
hi
CD62L
hi
CD127
hi
), effector (CD4
+
CD25
−
CD44
lo
CD62L
lo
CD127
lo-int
) or effector memory ͹Ͳ͹ 
(CD4
+
CD25
−
CD44
hi
CD62L
lo
CD127
int-hi
) T cells using a BD FACS ARIA II (BD Biosciences). T cell subset purity ͹Ͳͺ 
was >98%. Naïve CD4
+
 T cells were cultured in RPMI-1640 supplemented with 10% (v/v) FCS, 2mM L-͹Ͳͻ 
glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 50µM 2-͹ͳͲ 
mercaptoethanol. 1 x 10
5 
CD4 T cells were activated by plate bound anti-CD3 (1μg/ml; 145-2C11, R&D ͹ͳͳ 
Systems) and soluble anti-CD28 (5μg/ml; 37.51, eBioscience). Where indicated, CD4+ T cells were rested ͹ͳʹ 
for 48 hours in the absence of stimulatory antibodies or cytokines (see Supplementary Fig. 2a). CD4
+
 T ͹ͳ͵ 
cells from the inguinal lymph nodes of mBSA-immunized and non-immunized mice were derived using a ͹ͳͶ 
CD4
+
 T cell isolation kit (Miltenyi Biotec) and treated with IL-6 for 30 min with anti-CD3/CD28 ͹ͳͷ 
stimulation. Human peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood as ͹ͳ͸ 
previously described
54
. Naïve (CD3
+
CD4
+
CD45RO
lo
CD62L
hi
CCR7
hi
), central memory ͹ͳ͹ 
(CD3
+
CD4
+
CD45RO
hi
CD62L
hi
CCR7
hi
), effector (CD3
+
CD4
+
CD45RO
lo
CD62L
lo
CCR7
lo
) or effector memory ͹ͳͺ 
(CD3
+
CD4
+
CD45RO
hi
CD62L
lo
CCR7
lo
) CD4
+
 T cells were then purified using a BD FACS ARIA II (BD ͹ͳͻ 
Biosciences). To investigate the involvement of protein tyrosine phosphatases CD4 T cells were pre-͹ʹͲ 
treated (5 min) with 5mM sodium orthovanadate (New England BioLabs (UK) Ltd) prior to subsequent ͹ʹͳ 
stimulation. ͹ʹʹ 
Histological analysis- Formalin-fixed paraffin-embedded knee joints from AIA-challenged mice were ͹ʹ͵ 
prepared for immunofluorescent and immunohistochemical detection of antigens as described ͹ʹͶ 
previously
51
. For immunofluorescence, sections were rehydrated and antigen retrieval performed in ͹ʹͷ 
10mM sodium citrate buffer containing 0.05% (v:v) Tween 20 (95°C, 40 min). Sections were incubated ͹ʹ͸ 
with 10% (v:v) goat or swine serum appropriate to the secondary antibody. Cells positive for CD3 and ͹ʹ͹ 
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intracellular phospho-STAT1 and STAT3 were detected using CD3 (A0452, Dako), and pY-STAT1 (Tyr701; ͹ʹͺ 
58D6) or pY-STAT3 (Tyr705; D3A7) specific antibodies from Cell Signaling Technologies. For CD3 staining, ͹ʹͻ 
primary antibody detection was performed using biotinylated swine anti-rabbit IgG (E0431, Dako) with ͹͵Ͳ 
streptavidin-APC (BD Biosciences). For pY-STAT1 and pY-STAT3 detection a secondary rabbit anti-goat ͹͵ͳ 
IgG Alexa Fluor 488 antibody (Life Technologies) was used. Slides were mounted with Prolong Gold ͹͵ʹ 
Antifade with DAPI nuclear counterstain (Invitrogen). Images were collected using a Zeiss Apotome ͹͵͵ 
microscope and analyzed using ImageJ software. For immunohistochemistry, antigens were detected in ͹͵Ͷ 
paraffin sections using antibodies against CD3 (A0452, Dako), pY-STAT1 (Tyr701; 58D6) and PTPN2 ͹͵ͷ 
(AF1930, R&D Systems). Antigen retrieval was performed as above, and endogenous peroxidase activity ͹͵͸ 
blocked using 3% (v:v) H2O2. Antibody labelling was detected using biotinylated secondary antibodies ͹͵͹ 
(Dako, E0431), the Vectastain ABC kit and diaminobenzidine (Vector Laboratories). Sections were ͹͵ͺ 
counterstained with haematoxylin. Images were collected using Leica DM 2000 Led and quantification of ͹͵ͻ 
staining performed using the Leica QWin microscope imaging software.  ͹ͶͲ 
Flow cytometry- Analysis was performed as described previously
7, 8, 15
. For the intracellular detection of ͹Ͷͳ 
STAT1 and STAT3 phosphorylation, purified CD4
+
 T cells were fixed in 2% (w:v) paraformaldehyde for 15 ͹Ͷʹ 
min at 37⁰C, followed by permeabilization in 90% (v:v) methanol at -20⁰C for 3hrs. Cells were stained for ͹Ͷ͵ 
CD4 and phosphorylated STAT1, STAT3 
7
. To evaluate effector cytokine production, CD4
+
 T cells were ͹ͶͶ 
stimulated with 50ng PMA (phorbol 12-Myristate 13-Acetate), 500ng ionomycin and 3µM monesin for 4 ͹Ͷͷ 
hours prior to flow cytometric analysis
7, 8, 15
. Cells were acquired on a CyAn ADP analyzer (Beckman-͹Ͷ͸ 
Coulter) and analysed using Summit (software v4.3, Beckman-Coulter) or FlowJo 10 (TreeStar). For ͹Ͷ͹ 
imaging flow cytometry, cells were resuspended in 100 µl of PBS and acquired using the ImageStream ͹Ͷͺ 
imaging flow cytometer (Amnis). For co-localization analysis ImageStream software IDEAS (Amnis) was ͹Ͷͻ 
used.  ͹ͷͲ 
RNA purification and Q-PCR- For quantitative real-time PCR (Q-PCR), and Affymetrix gene chip analysis, ͹ͷͳ 
total RNA was extracted from purified or cultured CD4 T cells using the RNeasy Mini Kit (Qiagen) and ͹ͷʹ 
QIAshredders (Qiagen). Contaminating genomic DNA was removed by on-column DNase digestion ͹ͷ͵ 
(Qiagen). RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit with ͹ͷͶ 
RNase Inhibitor kit (Life Technologies). Gene expression was determined by Q-PCR
8, 55
 using the ͹ͷͷ 
QuantStudio 12K Flex Real-Time PCR system and the following TaqMan probes from Thermofisher: Ahr ͹ͷ͸ 
(Mm00478932_m1), Bcl3 (Mm00504306_m1 ), Bcl6 (Mm01342164_m1), Il10 (Mm00439614_m1), Il21 ͹ͷ͹ 
(Mm00517640_m1), Irf1 (Mm01288580_m1), Socs3 (Mm00545913_s1), Stat3 (Mm01219775_m1), Pim1 ͹ͷͺ 
(Mm00435712_m1) and Actb (Mm01205647_g1) as a housekeeping gene. Relative mRNA expression ͹ͷͻ 
was determined by the comparative cycle threshold (CT) method and normalised to the gene Actb.  ͹͸Ͳ 
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Affymetrix microarray and transcriptomic analysis- Purification of high quality RNA (RNA integrity ͹͸ͳ 
number >8.5) was confirmed using Agilent RNA Nano microfluidic chips using a 2100 Bioanalyzer ͹͸ʹ 
Instrument (Agilent Technologies). Expression profiling was performed in triplicate using Affymetrix ͹͸͵ 
Mouse GeneChip® 2.0ST microarrays (Affymetrix). Single-stranded cDNA was synthesized using the ͹͸Ͷ 
Ambion® WT (Whole Transcript) Expression Kit with the Affymetrix® Genechip® Poly-A RNA Control Kit ͹͸ͷ 
and Terminal Labelling kit. Arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix). Raw ͹͸͸ 
Affymetrix data files (CEL files) were imported into an in-house analysis pipeline written in R (version ͹͸͹ 
3.1.1) using Bioconductor packages, namely limma, affy and oligo
56, 57, 58, 59
. Data were background ͹͸ͺ 
corrected, log2 transformed and quantile normalized using the oligo package (RMA) “best practice”. ͹͸ͻ 
Differentially expressed genes and transcripts were identified using the limma package “best practice” ͹͹Ͳ 
workflow and P-values were corrected by multiple testing using Benjamini-Hochberg (false discovery ͹͹ͳ 
rate)
57
. ͹͹ʹ 
Bespoke coding (Perl) (Code available on request) was used to unite data over all conditions. To identify ͹͹͵ 
differentially expressed genes over all experiments, we selected the genes that were classified as having ͹͹Ͷ 
altered expression (either decreasing or decreasing) by a difference of 1.5-fold or greater, with a ͹͹ͷ 
significant value P≤0.05 and a minimal expression value of 150 relative intensity units. Only transcripts ͹͹͸ 
fulfilling all these selection criteria in three independent microarray experiments were included in the ͹͹͹ 
analysis. Files were also created in the input format required for molecular and pathway analysis using ͹͹ͺ 
Metacore integrated software suite (Thomson Reuters)
59
 and Ingenuity Pathway Analysis (IPA, ͹͹ͻ 
http://www.ingenuity.com/products/ipa). Transcriptome matrix visualization and hierarchical clustering ͹ͺͲ 
were performed using Morpheus software (https://software.broadinstitute.org/morpheus/). Circos plot ͹ͺͳ 
were obtained using the Circos software (http://circos.ca/software/)
60
. Networks were visualization and ͹ͺʹ 
analysed using the open sourced program Gephi (0.9.1) (https://gephi.org/). Microarray data have been ͹ͺ͵ 
deposited in ArrayExpress under Accession code E-MTAB-7682. ͹ͺͶ 
RNA-sequencing- Open access datasets from IL-6 treated Stat1
-/-
 and Stat3
-/-
 T cells (GSE65621) were ͹ͺͷ 
obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house ͹ͺ͸ 
bioinformatic pipeline. Briefly, RNA-seq single-end fastq files were mapped to mouse assembly GRCm38 ͹ͺ͹ 
using STAR
61
. Transcript counts were produced with FeatureCounts
62
 and data normalised using the ͹ͺͺ 
Bioconductor package, DeSeq2
63
 obtaining gene expression values as FPKM (Fragments Per Kilobase ͹ͺͻ 
Million). ͹ͻͲ 
For the human samples, RNA from homogenised synovial tissue was extracted in Trizol. 1μg total RNA ͹ͻͳ 
was used as input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). ͹ͻʹ 
Generated libraries were amplified with 10 cycles of PCR. Library size was confirmed using 2200 ͹ͻ͵ 
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TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and concentration was ͹ͻͶ 
determined by Q-PCR based method using Library quantification kit (KAPA). Libraries were multiplexed ͹ͻͷ 
(five per lane) and sequenced on Illumina HiSeq2500 (Illumina) to generate 50 million paired-end 75 base ͹ͻ͸ 
pair reads. Transcript abundance was derived using Kallisto v0.43.0 with GENCODE v24/GRCh38 as ͹ͻ͹ 
reference
64
. Transcript abundances were summarised over transcript isoforms using Bioconductor ͹ͻͺ 
package tximport 1.4.0. Imported abundances were processed using DESeq2 1.14.1 and transformed as ͹ͻͻ 
regularised log expression (RLE). Statistical analysis of gene-gene correlations was performed using ͺͲͲ 
Pearson correlation. P values were adjusted using false discovery rate (FDR) correction (Benjamini-ͺͲͳ 
Hochberg). RNA-seq data have been deposited in ArrayExpress under Accession code E-MTAB-6141. ͺͲʹ 
Chromatin Immunoprecipitation (ChIP)-seq- STAT1 and STAT3 chromatin Immunoprecipitation was ͺͲ͵ 
performed as previously described
20
. Briefly, 1x10
7
 naïve (TN) and effector memory (TEM) CD4
+
 T cells ͺͲͶ 
were activated for 1h with 20ng/ml IL-6 in the presence of antibodies against CD3 and CD28 (as ͺͲͷ 
described earlier). Genomic DNA was extracted, cross-linked and fragmented by sonication prior to ͺͲ͸ 
overnight incubation with 5ug of anti-STAT1 (sc-592, Santa Cruz Biotechnology) or anti-STAT3 (sc-482, ͺͲ͹ 
Santa Cruz Biotechnology) antibodies. The quality of the immunoprecipitation was confirmed by ChIP-ͺͲͺ 
qPCR for Irf1 and Socs3. To minimize systematic biases in the downstream data, an input reference ͺͲͻ 
control sample (chromatin taken before ChIP) was used to correct for genomic copy number variations, ͺͳͲ 
sonication-induced fragmentation bias, and chromatin accessibility. ChIP-seq libraries for Ion Torrent ͺͳͳ 
sequencing were prepared according to manufacturer’s instructions (# 4473623, Ion ChIP-Seq Library ͺͳʹ 
Preparation on the Ion Proton TM System). Briefly, DNA fragments were end-repaired and ligated to ion-ͺͳ͵ 
compatible adapters. Libraries were amplified and size-selected for insert lengths of approximately 100-ͺͳͶ 
250bp. Between 40M to 70M reads were obtained for each sample and mapped to Murine Genome ͺͳͷ 
Build GRCm38 (mm10) using the Ion Proton recommended mapper, Bowtie2
65, 66
. Reads were removed ͺͳ͸ 
where mapping quality was less than q20 (phred score) and peaks called using HOMER (Hypergeometric ͺͳ͹ 
Optimization of Motif EnRichment). To identify putative peaks in both ChIP and input, we first used ͺͳͺ 
HOMER findPeaks with a False Discovery Rate (FDR) value of 0.05. To identify sample peaks in the ͺͳͻ 
context of input, we then used HOMER findPeaks with the default parameters (Fold Change > 4-fold, P-ͺʹͲ 
value < 0.0001). Peaks were visualised using Integrative Genomics Viewer (IGV 2.3.88
67
). Available p300 ͺʹͳ 
ChIP-seq fastq files from CD4
+
 T cells, TH1, TH2 (GSE40463) and TH17 (GSE60482) were obtained from GEO ͺʹʹ 
(https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house pipeline. Reads were ͺʹ͵ 
mapped to the same mm10 assembly using BWA. All reads with a mapping quality less than q20 were ͺʹͶ 
removed. HOMER 
i
software was used to locate P300 enhancer elements (using the Homer option, –style ͺʹͷ 
super) and parameters Fold Change > 2-fold, P-value < 0.0001. To align STAT1 or STAT3 peaks with SE ͺʹ͸ 
regions, overlapping loci identified by STAT1 and STAT3 ChIP-seq and p300 ChIP-seq were identified ͺʹ͹ 
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using bedtools (http://bedtools.readthedocs.io/en/latest/)
68
. ChIP-Seq data have been deposited in ͺʹͺ 
ArrayExpress under Accession code E-MTAB-6273. ͺʹͻ 
ChIP-qPCR- To validate STAT-binding to promoter regions, Taqman custom assays were designed (see ͺ͵Ͳ 
Supplementary Table 2 for oligonucleotide primer sequences) and qPCR performed using a QuantStudio ͺ͵ͳ 
12K Flex Real-Time PCR System. For analysis of SP1, chromatin immunoprecipitation was conducted as ͺ͵ʹ 
previously described using 5ug of SP1 antibody (#17-601, Millipore) or isotype specific IgG control. ͺ͵͵ 
Analysis by qPCR used oligonucleotide primer sequences to the promoter regions of Irf1, Socs3, Stat3, ͺ͵Ͷ 
Cd274, Il4ra, Junb and Socs1 (Supplementary Table 2). Specific enrichment was normalised by ͺ͵ͷ 
subtracting the IgG control values from those derived for the input and antibody specific ͺ͵͸ 
immunoprecipitation samples. Value were expressed as 2^
ΔCT
.  ͺ͵͹ 
Motif finding- MEME Suite 4.11.2 software was used to discover de novo enriched DNA consensus ͺ͵ͺ 
sequences present in peaks identified within the STAT1 or STAT3 ChIP-seq datasets. All sequence ͺ͵ͻ 
predictions derived from MEME based on the interaction of known transcription factors with target DNA ͺͶͲ 
sequences where substantiated using STAMP
69
 (http://benoslab.pitt.edu/stamp/) and JASPAR database ͺͶͳ 
(http://jaspar.genereg.net/cgi-bin/jaspar_db.pl)
70
. ͺͶʹ 
Statistics- To determine the statistical significance of differences between data sets, Two-tailed unpaired ͺͶ͵ 
Student’s t-test were performed when two populations were compared. One-way ANOVA followed ͺͶͶ 
Tukey’s comparison test was used for multiple comparisons, unless otherwise specified, conducted using ͺͶͷ 
GraphPad Prism 5 (GraphPad Software). Statistical significance is also highlighted with the following ͺͶ͸ 
notations: *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. P ≤ 0.05 was considered significantly ͺͶ͹ 
different.  ͺͶͺ 
Reporting Summary- Further information on experimental design is available in the Life Sciences ͺͶͻ 
Reporting Summary linked to this article. ͺͷͲ 
Data Availability- Microarray, ChiP-seq and RNA-seq data have been deposited in ArrayExpress under ͺͷͳ 
Accession code E-MTAB-7682, E-MTAB-6273 and E-MTAB-6141, respectively. Available p300 ChIP-seq ͺͷʹ 
fastq files from CD4 T cells, Th1, Th2 (GSE40463) and Th17 (GSE60482), and Stat1
-/-
 and Stat3
-/-
 T cells ͺͷ͵ 
(GSE65621) were obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/). Access to interactive data ͺͷͶ 
sets can be found at www.jones-cytokinelab.co.uk (see relevant Figure Legends for additional ͺͷͷ 
information).  ͺͷ͸ 
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